HCM
Highline Capital Management Portfolio holdings
AUM
$51.6M
This Quarter Return
+15.58%
1 Year Return
-21.56%
3 Year Return
+183.68%
5 Year Return
+227.52%
10 Year Return
–
AUM
$1.45B
AUM Growth
+$1.45B
(-2.5%)
Cap. Flow
-$241M
Cap. Flow
% of AUM
-16.54%
Top 10 Holdings %
Top 10 Hldgs %
57.42%
Holding
45
New
10
Increased
7
Reduced
16
Closed
11
Top Buys
| 1 |
Take-Two Interactive
TTWO
|
$61M |
| 2 |
Marvell Technology
MRVL
|
$52.1M |
| 3 |
Moelis & Co
MC
|
$45.2M |
| 4 |
PVTL
Pivotal Software, Inc.
PVTL
|
$42.1M |
| 5 |
Sarepta Therapeutics
SRPT
|
$37.2M |
Top Sells
| 1 |
Equinix
EQIX
|
$101M |
| 2 |
ServiceNow
NOW
|
$78.1M |
| 3 |
CZR
Caesars Entertainment Corporation
CZR
|
$73.6M |
| 4 |
GRA
W.R. Grace & Co.
GRA
|
$57.3M |
| 5 |
IQVIA
IQV
|
$33.5M |
Sector Composition
| 1 | Healthcare | 33.07% |
| 2 | Consumer Discretionary | 27.69% |
| 3 | Materials | 15.95% |
| 4 | Technology | 9.4% |
| 5 | Communication Services | 4.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Royal Caribbean
RCL
$98.7B
| $121M | 7.6% | 1,055,250 -23,700 | -2% | -$2.72M |
|
|
2
IQVIA
IQV
$32.4B
| $108M | 6.81% | 753,596 -232,535 | -24% | -$33.5M |
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $94.7M | 5.95% | 1,066,249 +53,130 | +5% | +$4.72M |
|
|
BERY
4
DELISTED
Berry Global Group, Inc.
BERY
| $92.6M | 5.82% | 1,719,312 -609,362 | -26% | -$32.8M |
|
5
Elevance Health
ELV
$71.8B
| $80M | 5.03% | 278,858 -59,206 | -18% | -$17M |
|
6
Caesars Entertainment
CZR
$5.57B
| $75.8M | 4.76% | 1,623,745 -663,354 | -29% | -$31M |
|
|
GRA
7
DELISTED
W.R. Grace & Co.
GRA
| $73.1M | 4.59% | 936,400 -734,000 | -44% | -$57.3M |
|
8
Commercial Metals
CMC
$6.46B
| $69M | 4.33% | 4,039,008 +786,500 | +24% | +$13.4M |
|
|
9
Take-Two Interactive
TTWO
$43B
| $61M | 3.83% | +646,100 | New | +$61M |
|
10
Boyd Gaming
BYD
$6.88B
| $59.7M | 3.75% | 2,181,939 +11,000 | +0.5% | +$301K |
|
11
Rio Tinto
RIO
$102B
| $57.6M | 3.62% | 978,557 +316,700 | +48% | +$18.6M |
|
|
12
Marvell Technology
MRVL
$54.2B
| $52.1M | 3.28% | +2,621,400 | New | +$52.1M |
|
|
13
Sarepta Therapeutics
SRPT
$1.78B
| $52M | 3.27% | 436,000 +311,723 | +251% | +$37.2M |
|
14
VICI Properties
VICI
$36B
| $46.5M | 2.92% | 2,123,660 -7,600 | -0.4% | -$166K |
|
|
15
Moelis & Co
MC
$5.35B
| $45.2M | 2.84% | +1,086,935 | New | +$45.2M |
|
16
Pegasystems
PEGA
$9.27B
| $42.5M | 2.67% | 653,288 -61,050 | -9% | -$3.97M |
|
17
Ultragenyx Pharmaceutical
RARE
$2.89B
| $42.3M | 2.66% | 610,063 +151,550 | +33% | +$10.5M |
|
|
PVTL
18
DELISTED
Pivotal Software, Inc.
PVTL
| $42.1M | 2.65% | +2,020,850 | New | +$42.1M |
|
|
MTOR
19
DELISTED
MERITOR, Inc.
MTOR
| $38.8M | 2.44% | 1,905,780 -424,400 | -18% | -$8.64M |
|
20
UroGen Pharma
URGN
$900M
| $36.5M | 2.29% | 986,878 +525,200 | +114% | +$19.4M |
|
21
Las Vegas Sands
LVS
$39.6B
| $34.6M | 2.17% | +566,900 | New | +$34.6M |
|
|
FPAC.U
22
DELISTED
Far Point Acquisition Corporation Units, each consisting of one share of Class A common stock, $0.00
FPAC.U
| $21.6M | 1.36% | 2,076,099 -416,000 | -17% | -$4.33M |
|
23
Moderna
MRNA
$9.37B
| $18.9M | 1.19% | 930,230 -587,712 | -39% | -$12M |
|
24
Alector
ALEC
$238M
| $15.4M | 0.96% | +820,290 | New | +$15.4M |
|
25
Vale
VALE
$43.9B
| $12.9M | 0.81% | 984,224 -1,033,624 | -51% | -$13.5M |
|